Dendritic cell therapy is effective in all types of cancer, except blood cancer. The method has been available since 2002. Dendritic cell therapy can generally be used at any stage of the disease. The earlier it is used, the better the chances of success, especially in preventing relapses. While the exact number of scientific publications confirming the effectiveness of dendritic cell therapy is difficult to quantify, the therapy has been widely researched, with over 7,000 studies examining its potential.

Some types of leukemia—blood cancer—do not respond to DCT. Blood cancers typically have a more complex interaction with the immune system, which can compromise the success of DCT.

Although dendritic cell therapy (DCT) is known to many medical professionals, it has not yet been officially included in international guidelines for cancer treatment. The European Medicines Agency (EMA) allows individual member states to issue licenses for the use of this method, provided the treatment is performed under the supervision of appropriately qualified physicians. These physicians must also have access to a specialized clean room laboratory for the preparation of the therapy.

In Europe, Germany is one of the few countries to have implemented this legal framework, allowing licensed physicians to offer DCT as part of an integrative cancer treatment approach. However, only three physicians in Germany are authorized to produce and administer the cells to patients.

Dendritic cell therapy (DCT) may be an alternative to chemotherapy in certain cases, particularly after surgical resection of the primary tumor. However, given the long-proven efficacy of standard therapies, including chemotherapy and radiation, these treatments are recommended as primary options. It is well documented that chemotherapy and radiation can damage tumor cells, making them more vulnerable to detection and destruction by the immune system. Combining conventional cancer therapies with DCT may therefore improve therapeutic outcomes by harnessing both the direct effects of conventional therapies and the immune system's ability to recognize and eliminate damaged tumor cells.

Dendritic cell therapy (DCT) can be combined with conventional chemotherapy, drug immunotherapies or radiotherapy as part of a comprehensive treatment plan.

Dendritic cell therapy (DCT) can be used at any stage of cancer, although its effectiveness is greatest when the tumor burden is small. This typically occurs when the tumor is discovered at an early stage or after surgical resection. In these cases, DCT is ideally used as an adjuvant therapy to prevent tumor recurrence and maintain the patient's overall health. The immune system generally functions more effectively when the tumor mass is smaller, increasing the likelihood of a successful response to therapy. As with chemotherapy and radiotherapy, early initiation of DCT is associated with more favorable outcomes.
In cases where the cancer is already advanced, DCT serves as a palliative care approach, focusing on relieving symptoms, prolonging life, and improving quality of life. This approach aims to control disease progression while maintaining the patient's well-being.

Dendritic cell therapy (DCT) is generally considered safe because the dendritic cells used for treatment are taken from the patient's own immune system, reducing the risk of immunological rejection. The most commonly observed side effect is a mild, temporary fever after injection, which usually subsides within a few hours. Other, less common side effects may include fatigue, local redness or swelling at the injection site, and mild flu-like symptoms. These effects are usually short-lived and represent a natural response to the activation of the immune system. Side effects may also depend on the type and location of the tumor. In rare cases, other side effects such as nausea, diarrhea, vomiting, decreased platelet count, anemia, and typical reactions associated with injections or infusions have been reported. Serious adverse events are rare and are usually closely monitored in the clinical setting.

Because dendritic cells play a crucial role in regulating immune responses and maintaining immune tolerance, their potential for treating autoimmune diseases has also been explored. In autoimmune diseases, the immune system mistakenly attacks the body's own tissues, and DCT has been studied for its ability to modulate these immune responses. Patients suffering from an autoimmune disease should consult their physician before considering DCT.

You will attend two appointments at our private clinic in Germany:

The first appointment is the blood draw. We will take 200 ml of your blood. The blood sample will then go directly to our clean-room laboratory, where our experts will begin preparing your personalized dendritic cell vaccination.

The visit lasts approximately two hours and includes a consultation with the physician, an examination, a blood draw, and the administration of a high-dose vitamin C infusion and a vitamin D3 injection, which is included in the price.

The laboratory needs seven days to prepare the appropriate preparation from your cells.

The second appointment is the dendrite injection. This appointment takes place exactly one week after the blood draw. The appointment lasts approximately two hours and involves the administration of the injection under your skin. You will remain in the clinic for an observation period and receive another cycle of high-dose vitamin C/D.

We strongly advise you to continue to attend regular follow-up appointments with your oncologist to monitor tumor progression and overall health, including routine exams and scans. Participation in the Terrain-Ten™ program, described on the website, is very helpful.

Costs depend heavily on the type of cancer, its stage, and the personalized additional treatment programs proposed to the patient. One cycle of DCT alone costs approximately EUR 20,000.

The availability and coverage of this treatment may vary from country to country and depends on local health regulations and the specifics of your insurance plan.

The treatment is only carried out in three private clinics in Europe, all of which are located in Germany.

In most European countries, with the exception of Germany, dendritic cell therapy (DCT) has not yet been officially approved by the respective health authorities. Furthermore, the transport of dendritic cells across borders is generally prohibited because there is no guarantee of the viability or efficacy of the cells after transport, which may not meet regulatory standards for clinical use. This is in line with European Union regulations governing the transport of human cells and cell-based therapies.

Founded in 2018 by Bruno Rosset, the IASO Cancer Initiative aims to improve treatment outcomes and the quality of life of cancer patients worldwide. The initiative provides access to cutting-edge, scientifically validated cancer therapies, many of which are not yet widely accepted or are only available at select locations worldwide. To date, the network includes eight advanced clinics specializing in integrative cancer treatment. The physicians in this network are leading experts and pioneers in the field of cancer immunotherapy.

Iaso is the Greek goddess of recovery and healing, associated with the processes of recovery, healing, and the restoration of health. A figure in Greek mythology, she is worshipped as a goddess who oversees the healing process and all paths to recovery.

Iaso is the daughter of Epione, the goddess of comfort and consolation, and Asclepius, the Greek god of medicine and healing (often referred to as Aesculapius in Roman mythology). Asclepius is widely known for his ability to heal and restore life, and as his daughter, Iaso embodies the restoration aspect of healing in ancient Greek belief.

We work exclusively with accredited clinics that meet strict standards and, among other things, have their own GMP-certified clean room laboratories. Furthermore, the specialists at these clinics have conducted and published their own scientific studies to demonstrate the effectiveness of our therapies.

Our clinics hold all the necessary licenses, certifications, and approvals from the German health authorities, ensuring compliance with national regulations. We are happy to provide copies of these documents upon request.

We strive to provide you with personalized advice and support, help you make informed decisions about choosing the appropriate treatment, and accompany you throughout the entire treatment process.